Kids Capital Management L.P. Takes $7.93 Million Position in Illumina, Inc. $ILMN

Key Points

• Kids Capital Management L.P. has invested approximately $7.93 million to acquire 100,000 shares of Illumina, making it the firm's 6th largest position at 8.7% of its portfolio.
• Illumina's stock price has seen a recent decline of 1.0%, opening at $100.09, with analysts providing a diverse range of ratings and price targets.
• Despite a net margin decrease and a revenue drop of 4.8% year-over-year, Illumina beat EPS expectations with $1.19, surpassing analysts' consensus of $1.02.

Kids Capital Management L.P. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The fund acquired 100,000 shares of the life sciences company's stock, valued at approximately $7,934,000. Illumina makes up 8.7% of Kids Capital Management L.P.'s portfolio, making the stock its 6th biggest position. Kids Capital Management L.P. owned about 0.06% of Illumina as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Diversified Trust Co acquired a new position in Illumina during the 1st quarter valued at approximately $355,000. State of Alaska Department of Revenue boosted its holdings in Illumina by 2.5% during the first quarter. State of Alaska Department of Revenue now owns 18,527 shares of the life sciences company's stock worth $1,469,000 after buying an additional 445 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Illumina by 4.9% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 199,176 shares of the life sciences company's stock worth $15,803,000 after buying an additional 9,252 shares in the last quarter. Merit Financial Group LLC lifted its holdings in Illumina by 344.8% during the first quarter. Merit Financial Group LLC now owns 13,036 shares of the life sciences company's stock valued at $1,034,000 after purchasing an additional 10,105 shares in the last quarter. Finally, Citigroup Inc. lifted its holdings in Illumina by 13.5% during the first quarter. Citigroup Inc. now owns 150,764 shares of the life sciences company's stock valued at $11,962,000 after purchasing an additional 17,985 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company's stock.

Analyst Upgrades and Downgrades

ILMN has been the subject of several recent analyst reports. Daiwa Capital Markets cut shares of Illumina from an "outperform" rating to a "neutral" rating and set a $94.00 price objective for the company. in a research report on Tuesday, August 12th. Daiwa America cut shares of Illumina from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 12th. Citigroup cut shares of Illumina from a "hold" rating to a "strong sell" rating and dropped their price target for the company from $85.00 to $80.00 in a research report on Wednesday, July 9th. JPMorgan Chase & Co. dropped their price target on shares of Illumina from $120.00 to $85.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Finally, Guggenheim dropped their price target on shares of Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Seven analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $124.58.

Illumina Stock Up 1.1%

Shares of NASDAQ ILMN traded up $1.07 during midday trading on Tuesday, hitting $101.60. The company's stock had a trading volume of 1,024,600 shares, compared to its average volume of 2,352,529. The business's fifty day simple moving average is $97.12 and its two-hundred day simple moving average is $89.34. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.81 and a quick ratio of 1.41. Illumina, Inc. has a 1 year low of $68.70 and a 1 year high of $156.66. The firm has a market capitalization of $15.62 billion, a price-to-earnings ratio of 12.86, a price-to-earnings-growth ratio of 2.25 and a beta of 1.37.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The business had revenue of $1.06 billion during the quarter, compared to analyst estimates of $1.12 billion. During the same quarter last year, the firm posted $0.36 earnings per share. The business's revenue for the quarter was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, equities analysts predict that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.